S&P 500   4,638.82 (+1.57%)
DOW   34,892.87 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
S&P 500   4,638.82 (+1.57%)
DOW   34,892.87 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
S&P 500   4,638.82 (+1.57%)
DOW   34,892.87 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
S&P 500   4,638.82 (+1.57%)
DOW   34,892.87 (+1.19%)
QQQ   398.13 (+1.09%)
AAPL   168.03 (+1.65%)
MSFT   334.16 (+1.08%)
FB   325.41 (+0.29%)
GOOGL   2,903.44 (+2.31%)
AMZN   3,529.50 (+0.64%)
TSLA   1,150.50 (+0.50%)
NVDA   326.98 (+0.07%)
BABA   127.16 (-0.29%)
NIO   39.95 (+2.10%)
CGC   10.69 (-0.19%)
AMD   157.03 (-0.85%)
GE   95.71 (+0.76%)
MU   87.74 (+4.45%)
T   22.94 (+0.48%)
F   20.25 (+5.52%)
DIS   147.05 (+1.48%)
ACB   6.39 (-0.47%)
PFE   53.53 (-0.37%)
AMC   33.83 (-0.32%)
BA   198.31 (+0.23%)
NASDAQ:HALO

Halozyme Therapeutics Stock Forecast, Price & News

$32.92
+0.04 (+0.12%)
(As of 12/1/2021 10:39 AM ET)
Add
Compare
Today's Range
$32.85
$33.23
50-Day Range
$32.88
$41.97
52-Week Range
$32.52
$56.40
Volume
5,830 shs
Average Volume
1.00 million shs
Market Capitalization
$4.63 billion
P/E Ratio
11.80
Dividend Yield
N/A
Beta
1.28
30 days | 90 days | 365 days | Advanced Chart
Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Halozyme Therapeutics logo

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
136
Year Founded
1998

Sales & Book Value

Annual Sales
$267.59 million
Cash Flow
$1.06 per share
Book Value
$1.12 per share

Profitability

Net Income
$129.09 million
Pretax Margin
57.66%

Debt

Price-To-Earnings

Miscellaneous

Free Float
137,127,000
Market Cap
$4.63 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

Social Links


MarketRank

Overall MarketRank

2.75 out of 5 stars

Medical Sector

40th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

4th out of 202 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -












Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

Is Halozyme Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics
or view top-rated stocks.

How has Halozyme Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HALO shares have increased by 80.7% and is now trading at $32.92.
View which stocks have been most impacted by COVID-19
.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Halozyme Therapeutics
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $1.06. The biopharmaceutical company earned $115.83 million during the quarter, compared to analysts' expectations of $101.94 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 187.85% and a net margin of 88.36%. During the same quarter last year, the firm earned $0.25 earnings per share.
View Halozyme Therapeutics' earnings history
.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of $1.900-$2.000 for the period. The company issued revenue guidance of $430 million-$445 million.

What price target have analysts set for HALO?

8 brokerages have issued 12-month target prices for Halozyme Therapeutics' shares. Their forecasts range from $41.00 to $65.00. On average, they expect Halozyme Therapeutics' stock price to reach $53.00 in the next twelve months. This suggests a possible upside of 61.0% from the stock's current price.
View analysts' price targets for Halozyme Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 58, Pay $1.52M)
  • Ms. Elaine D. Sun, Sr. VP & CFO (Age 49, Pay $859.58k)
  • Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 57, Pay $710.18k) (LinkedIn Profile)
  • Mr. Masaru Matsuda Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50, Pay $707.84k)
  • Mr. Ed Gemo, VP, Chief Information & Security Officer
  • Mr. Albert S. Kildani, VP of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox, VP of HR
  • Mr. William J. Fallon, Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances (Age 64)
  • Dr. Steve Knowles, Chief Medical Officer
  • Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.71%), Artisan Partners Limited Partnership (7.16%), Invesco Ltd. (3.79%), William Blair Investment Management LLC (3.55%), Macquarie Group Ltd. (2.13%) and Geode Capital Management LLC (1.75%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics
.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Citigroup Inc., Third Security LLC, Schroder Investment Management Group, Invesco Ltd., Two Sigma Investments LP, Eagle Asset Management Inc., and Morgan Stanley. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, Jean-Pierre Bizzari, Kenneth J Kelley, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics
or view top insider-selling stocks.

Which major investors are buying Halozyme Therapeutics stock?

HALO stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Arrowstreet Capital Limited Partnership, Goldman Sachs Group Inc., Allianz Asset Management GmbH, Alliancebernstein L.P., BlackRock Inc., CastleArk Alternatives LLC, and Voya Investment Management LLC.
View insider buying and selling activity for Halozyme Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $32.92.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics has a market capitalization of $4.63 billion and generates $267.59 million in revenue each year. The biopharmaceutical company earns $129.09 million in net income (profit) each year or $2.79 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

Halozyme Therapeutics employs 136 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?

The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

When was Halozyme Therapeutics founded?

Halozyme Therapeutics was founded in 1998.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

Where are Halozyme Therapeutics' headquarters?

Halozyme Therapeutics is headquartered at 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at [email protected], or via fax at 858-704-8311.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.